scorecardresearch
Add as a preferred source on Google
Monday, April 20, 2026
TopicBig Pharma

Topic: Big Pharma

Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.

‘Can hamper entry of new drugs’ — groups raise alarm over IP proposals part of India-EFTA talks

India & EFTA (Iceland, Liechtenstein, Norway and Switzerland) are negotiating Trade and Economic Partnership Agreement (TEPA) that is likely to be finalized within next few weeks.

Novartis, Eli Lilly oppose compulsory licences for breast cancer drugs, say sales up despite price

Pharma giants were responding to petition in Kerala HC seeking compulsory licences for their HER2-negative breast cancer drugs, which would allow cheaper, generic versions to be made.

India banks on Hyderabad’s ‘Pharma City’ to break China’s stranglehold over drug supplies

India’s $42 billion drug manufacturing industry relies intensely on China, which supplies almost 70% of the active pharmaceutical ingredients that go into making medicines.

Who’s responsible if vaccines go wrong? Pharma companies or govts? There are no easy answers

Given the speed of vaccine production, there are few answers for what Pharma companies & govts are ultimately responsible for.

Covid pandemic gives businesses plenty of reasons to get back to dealmaking

It was the pharma industry that kicked off the global megamerger wave last time around, in early 2014.

Big pharma is looking beyond coronavirus with AstraZeneca eyeing merger with Gilead

The suggestion of a blockbuster merger between the two drugmakers is a sign that the industry is getting back to something resembling business as usual.

Big Pharma has failed. It’s been 35 years since a new class of antibiotics entered the market

Antibiotics are among the most important medicines known to humankind, but we are running out of it.

Lucrative drugs like Viagra, Humira to lose patents but Indian pharma unlikely to gain

Indian pharma companies, which have dominated the world’s generic medicines market, are now hampered by Trump’s policies & lack of expertise in biologics.

How Ranbaxy faked manufacturing data for all drugs not only in India, but in US, Europe too

Ranbaxy was treating data as an entirely fungible marketing tool, apparently without consideration of impact on patients. It was an outright fraud.

On Camera

India’s close encounters with Pakistan on Siachen

Pakistan's SSG team was not adequately provisioned for the inclement weather. If it managed to consolidate its position, the story of Siachen would have been different. 

The rebirth of YES BANK, a financial thriller: How captains of industry brought it back from the brink

In March 2020, Prashant Kumar took over as CEO & MD overseeing YES Bank reconstruction. He was ably supported by veteran banker Sunil Mehta, CA Atul Bheda & consultant Mahesh Krishnamurti.

Why Siliguri Corridor is strategically important for India & how it is being secured | Cut The Clutter

This special edition of Cut The Clutter, straight from the Siliguri corridor, details the strategic importance of the narrow strip of land in West Bengal, and how it’s a vital link connecting the Northeast to the rest of India.

Trump, Netanyahu’s Iran gamble: The regime change rebound

American objectives are unmet. They neither have muscle nor motivation to resume the war. As for Iran, the regime didn’t just survive, it’s now led by more radical individuals.